Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Issue 2 (1st February 2021)

• Record Type: Journal Article
• Authors: Obi, Ogugua Ndili; Lower, Elyse E.; Baughman, Robert P.
• Is Part Of: Expert review of clinical pharmacology. Volume 14:Issue 2(2021)
• Page Start: 179
• Page End: 210
• Publication Date: 2021-02-01
• Subjects: Sarcoidosis -- infliximab -- adalimumab -- rituximab -- repository corticotropin injection -- tumor necrosis factor; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2021.1878024
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction : Sarcoidosis is a multi-organ disease with a wide range of clinical manifestations and outcomes. A quarter of sarcoidosis patients require long-term treatment for chronic disease. In this group, corticosteroids and cytotoxic agents be insufficient to control disease Areas covered : Several biologic agents have been studied for treatment of chronic pulmonary and extra-pulmonary disease. A review of the available literature was performed searching PubMed and an expert opinion regarding specific therapy was developed. Expert opinion : These agents have the potential of treating patients who have progressive disease. Many of these agents have different mechanisms of action, response rates, and toxicity profiles.